Patrick Emmerling, PhD, MBA, joined the team at Roswell Park as Senior Licensing Manager in March 2015. In his current role as Director, Dr. Emmerling continues to work closely with Roswell Park inventors to facilitate the disclosure of new innovations; to develop and execute appropriate patenting and marketing strategies; assist Roswell Park inventors identify and apply for internal and external sources of technology development funding to de-risk their technologies, and negotiate license agreements with established and/or start-up companies to enable successful commercialization. Prior to coming to Roswell Park, Dr. Emmerling worked for four years as a Licensing Manager at the University of Rochester where he managed a large and diverse portfolio of physical and biomedical technologies.
Dr. Emmerling earned his bachelor of arts degree in Chemistry from the College of the Holy Cross, his doctoral degree in Physical Chemistry from The State University of New York at Buffalo, and his master of business administration degree from the Simon Business School at the University of Rochester.
Thanya McKinnon joined the Roswell Park Technology Transfer and Commercialization Development Team in September 2019. Prior to joining Roswell Park, she spent 17 years as a legal professional, with most of her experience in bankruptcy trial litigation. More recently she has worked in the field of academics and aerospace defense engineering.
Thanya McKinnon has earned an Associate Degree in Business Administration (1990) Bryant & Stratton College, Associate Degree in Legal Studies (1998) from Bryant & Stratton College and is currently a full-time student due to receive a bachelor’s degree in Community and Human Services in Spring 2020 from SUNY Empire State College with plans to attend law school thereafter.
Randy V. Clower, PhD, JD, joined the Roswell Park Technology Transfer and Commercial Development Team in 2019, bringing with him over a decade of legal and business-related experience pertaining to the commercialization of proprietary innovations for universities, cancer-centers, and various business entities.
Insofar as many translational technologies require nuanced value-capture strategies—from concept-stage throughout product development and maturation—Dr. Clower’s professional experience concerning federal and state funding initiatives, government policy, administrative guidelines, and experience with foreign and domestic IP statutes, provides a strong framework for assisting inventors and IP owners to achieve their commercial goals. Dr. Clower’s expertise, moreover, involves all forms of IP and commercial negotiations, e.g., licensing and joint-development agreements, as well as assessing market landscapes concerning immuno-oncological innovations, among other biomedical platforms.
Dr. Clower earned his PhD in Microbiology and Immunology from SUNY at Buffalo, as well as his JD with a concentration in Intellectual Property and Technology. He also earned his bachelor's in Molecular Genetics from SUNY Fredonia.